User login
Key clinical point: Risankizumab led to a significant improvement in patient-reported outcomes compared with placebo in patients with psoriatic arthritis (PsA) and an inadequate response to 1 or 2 biologics (Bio-IR) or ≥ 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR).
Major finding: At week 24, patients receiving risankizumab reported a significantly greater improvement in the mean pain index (−14.7 vs −6.5; P < .001), fatigue score (4.9 vs 2.6; P < .01), patient’s global assessment of disease activity (−16.5 vs −7.7; P < .001), general health status (0.09 vs 0.01; P < .001), and physical functioning (5.1 vs 2.0; P < .001), compared to placebo.
Study details: Findings are from the phase 3 KEEPsAKE2 study including 443 patients with active PsA and Bio-IR or csDMARD-IR who were randomly assigned to receive 150 mg risankizumab or placebo.
Disclosures: This study was funded by AbbVie. Four authors declared being employees or stockholders at AbbVie, and other authors reported ties with several sources, including AbbVie.
Source: Ostor AJK et al. Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: Analysis of the Phase 3 trial KEEPsAKE 2. RMD Open. 2022;8:e002286 (Jun 14). Doi: 10.1136/rmdopen-2022-002286
Key clinical point: Risankizumab led to a significant improvement in patient-reported outcomes compared with placebo in patients with psoriatic arthritis (PsA) and an inadequate response to 1 or 2 biologics (Bio-IR) or ≥ 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR).
Major finding: At week 24, patients receiving risankizumab reported a significantly greater improvement in the mean pain index (−14.7 vs −6.5; P < .001), fatigue score (4.9 vs 2.6; P < .01), patient’s global assessment of disease activity (−16.5 vs −7.7; P < .001), general health status (0.09 vs 0.01; P < .001), and physical functioning (5.1 vs 2.0; P < .001), compared to placebo.
Study details: Findings are from the phase 3 KEEPsAKE2 study including 443 patients with active PsA and Bio-IR or csDMARD-IR who were randomly assigned to receive 150 mg risankizumab or placebo.
Disclosures: This study was funded by AbbVie. Four authors declared being employees or stockholders at AbbVie, and other authors reported ties with several sources, including AbbVie.
Source: Ostor AJK et al. Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: Analysis of the Phase 3 trial KEEPsAKE 2. RMD Open. 2022;8:e002286 (Jun 14). Doi: 10.1136/rmdopen-2022-002286
Key clinical point: Risankizumab led to a significant improvement in patient-reported outcomes compared with placebo in patients with psoriatic arthritis (PsA) and an inadequate response to 1 or 2 biologics (Bio-IR) or ≥ 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR).
Major finding: At week 24, patients receiving risankizumab reported a significantly greater improvement in the mean pain index (−14.7 vs −6.5; P < .001), fatigue score (4.9 vs 2.6; P < .01), patient’s global assessment of disease activity (−16.5 vs −7.7; P < .001), general health status (0.09 vs 0.01; P < .001), and physical functioning (5.1 vs 2.0; P < .001), compared to placebo.
Study details: Findings are from the phase 3 KEEPsAKE2 study including 443 patients with active PsA and Bio-IR or csDMARD-IR who were randomly assigned to receive 150 mg risankizumab or placebo.
Disclosures: This study was funded by AbbVie. Four authors declared being employees or stockholders at AbbVie, and other authors reported ties with several sources, including AbbVie.
Source: Ostor AJK et al. Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: Analysis of the Phase 3 trial KEEPsAKE 2. RMD Open. 2022;8:e002286 (Jun 14). Doi: 10.1136/rmdopen-2022-002286